Invion Ltd. (AU:IVX) has released an update.
Invion Ltd has received HREC approval to begin a Phase I/II clinical trial of its drug INV043 for treating non-melanoma skin cancers, with patient screening and treatments expected to start next month at Veracity Clinical Research in Queensland. The company highlights the potential of INV043 to offer a more effective treatment with fewer side effects like scarring, based on promising preclinical studies. The trial is a significant step in Invion’s pursuit to improve cancer treatments and will also inform future trials, such as for anogenital cancer.
For further insights into AU:IVX stock, check out TipRanks’ Stock Analysis page.
